🔎 Trials Near Me

Home › Post-Concussion Syndrome › NCT04978571

Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)

Recruiting

A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)

Who can join

Ages 11 to 18 · All sexes

Full eligibility criteria
Concussion:

Inclusion Criteria:

* Clinical diagnosis of Post-Concussion Syndrome
* Post-Concussion Symptoms for at least 3 months along with lack of other explanation for their symptoms
* English and Spanish-speaking families

Exclusion Criteria:

* Seizure disorders
* Significant developmental delay
* Infection or severe dermatological condition of ear
* Bleeding disorders
* Implanted electrical device

COVID:

Inclusion Criteria

* Child is in between the ages 11-18
* Child is present at CHOC Neurology clinic post covid-19 symptoms of more than 3 months duration along with lack of other explanation for their symptoms
* English-speaking and Spanish-speaking families

You cannot participate in this study if you meet the following exclusion criteria:

* Children with significant developmental delay, infection or severe dermatological condition of ear, bleeding disorders, or having any implanted electrical device will be excluded.
* Are not able to attend Friday appointments for the Neurostim placements.

About the study

The purpose of this study is to test the effect of Auricular Percutaneous Electrical Nerve Field Stimulation (a Neurostim device) on children with pain and Post Concussion symptoms.

An additional purpose of this study is to demonstrate that PENFS improves functioning in children with post Covid-19 symptoms.

What is being tested

Sponsor: Children's Hospital of Orange County · Participants: 125 · Started: Feb 1, 2021

Contact the study team

Official record on ClinicalTrials.gov — NCT04978571

Locations in the U.S.

CaliforniaCHOC Children's, Orange

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.